Industry Experience

Product Development and Operations

Product Development and Operations

Product Development and Operations

 Proleukin - IL2 (Preclinical, IND)

Betaseron® 

(Phase 2-3, PLA/ELA, Market Launch, Established academic research program in Multiple Sclerosis) 

Enbrel® (Phase 2, 3) 

Actimmune® (Phase 2,3, BLA, new INDs) 

IL-4 Receptor (Phase 2, Corporate partner)

IL-1 Receptor (Phase 2, Corporate partners)

T-cell Receptor (Phase 2, out-license) 

ConXn® Relaxin (Phase 2)

Luxiq® (Phase 3, 505b2 NDA, Market Launch)

Olux® (Phase 1-2)

Fludara® (Market Launch) 

Thioplex® (NDA, Market Launch) 

Mitomycin C (out-license, Corporate partner) 

Etoposide (out-license, Corporate partner) 

Leucovorin Calcium (ANDA) 

Adefovir dipivoxil - Hepsera® (Phase 3) 

Tenofovir disoproxil -Viread® (Phase 2, 3) 

Vaccine Adjuvants (Discovery, IND, Phase1)

Ziconotide (Phase 3, NDA, MAA, Launch)

Ceftazidime/Avibactam (Phase 3, NDA, Corporate partnership)

Pexidartinib (Tulario) (IND to NDA)

Therapeutic Areas:

Product Development and Operations

Product Development and Operations

 Autoimmunity/Inflammation

- Multiple Sclerosis 

- Scleroderma

- Rheumatoid Arthritis 

- Osteoarthritis

- Crohns’ Disease 

- Asthma 


Oncology 

- Breast Cancer

- Colorectal Cancer

- Glioma 

- Malignant Melanoma

- Ovarian Cancer 

- Prostate Cancer

- Renal Cell Carcinoma

-  Lung Cancer


Metabolic Kidney Disease

Chronic Pain

Dermatology 

Infectious Diseases 

Anti-virals (HIV, Hepatitis B & C)

Gene Therapy (Viral and plasmid DNA)

- Hemophilia

- Parkinson's Disease

- Immunomodulation